Metraipolis › archive › dc_8a9dbbb2fcab

Economic evaluation of anlotinib plus penpulimab vs. sorafenib as first-line therapy for unresectable hepatocellular carcinoma in China — Europe PMC PMID:41404573

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41404573
DOI: 10.3389/fpubh.2025.1634266
License (as archived): solo-consultazione
Archived: 2026-11-08T03:00:15.960Z
SHA-256 of the archived text: 9d0b43206158de830d6b0d9df979d873b399429e7129d945a3f7d22f5b1b6525
Stable URL of this page: https://metraipolis.com/documento/dc_8a9dbbb2fcab

How to cite

Economic evaluation of anlotinib plus penpulimab vs. sorafenib as first-line therapy for unresectable hepatocellular carcinoma in China — Europe PMC PMID:41404573 — Europe PMC (en), https://europepmc.org/article/MED/41404573 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8a9dbbb2fcab (Metraipolis archive dc_8a9dbbb2fcab, sha256 9d0b43206158de830d6b0d9df979d873b399429e7129d945a3f7d22f5b1b6525)

BibTeX

@misc{dc8a9dbbb2fcab,
  title = {Economic evaluation of anlotinib plus penpulimab vs. sorafenib as first-line therapy for unresectable hepatocellular carcinoma in China — Europe PMC PMID:41404573},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41404573},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8a9dbbb2fcab; sha256 9d0b43206158de830d6b0d9df979d873b399429e7129d945a3f7d22f5b1b6525},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41404573. Agents can read the archived copy with the MCP tool read_document.